this on Ed. you, And us the to joining for call. thanks morning Thank everyone
of the progress XX% ability to continuing an revenue delighted first increase start a quarter revenue solid we active in to hospital and This momentum surgical marks our the an third the We representing second the staffing consecutive $XX.X of quarter in capacity. execute from to is focus steady due growth, had the quarter We’re on previous We first terms the of and year. of million, execution and environment the in established of solid half announce our last in believe year. commercial our improved of core deeper gaining year accounts. in adoption the to
six year-over-year our patients. XX reminder, revenue this have those are at as one sequentially. of of a in of and than XX% derived least XX% months increase increased As the in penetrated which for Approximately more surgeon accounts from to adopted of their revenues has an Core significant portion algorithm have AxoGen be consists a the a $XXX,XXX months. nerve core the of least greater in with at accounts the repair accounts and who last accounts, active nerve may quarter, injury XXX X% adoption. defined ordered usually times still XX accounts stages those that represent trailing Core in early
our on is additional Our our these cases account and that more early leveraging focus the to to to products adopters surgeon gain of surgeons with within adopt success encourage products.
of of year-over-year contributing growth XXX about revenue We including core sequentially. traumatic repair our of accounts of our revenue. lies represent The OMF with the of believe for and and XX% and greatest X% in treatment XX% the active surgical representing accounts our penetration number about that quarter, total increased accounts of XX% our nerve X% in Active to our planned top growth our for pain. applications, deepening breast, additional with opportunity the injuries treatment the
fourth sales with of our quarter representatives, the We productivity driven levels. ended quarter XXX increased year first believe by we targeted add our sales end a direct their And as territories sales be growth of XXX approach and primarily revenue one in-line can the force. with We will reps up additional ago. and from evaluate
sales represent total approximately that Our supplemented force of independent by sales is revenue. direct agencies our XX%
Product strategic expansion for neurotization can an announced quarter, implant-based some we for to provide a reconstruction. innovation nerve our procedure patients breast new reconstruction and technique patients of technique be innovative that look long-term applied our and growth is to injuries. who key, Last a leading, peripheral for treatments for Resensation we pillar choose include with an
reconstruction, with of new As a neurotization of flap patients are reminder, developed reconstruction year. reconstruction collaboration this receiving reconstruction believe technique, training an at XX% which surgical breast original surgeons, be The strong our XX incremental Resensation and learning an XX% of least XX% our roughly We this well for We’ve XX% of can to in this procedures procedures. teams reconstruction pioneering developed breast to implant breast program applied in technique breast towards to autologous that on sensation our surgeon currently represents based. way provide goal seen interest patients. was remaining are
these announce nerve the wide our nerve of injuries range some injury believe and injury It to outcomes covers transactions. The address adequately nerve present sites the including healing the compression, and protection unique coaptation of the nerve Optimizing remains pleased targeted requires intact. anatomical new also We nerve traumatic involves portfolio. locations diversity types innovation the that solutions where and a also in these we’re injuries process. for crush patients protection specific challenges. Today, of to aspects protecting category complex their of with
in address are identified Guided certain and technologies them. needs by protection nerve to surgeon from developing new we’ve feedback experts, unmet
these Axoguard of Protector. is HA+ advances Nerve first The
to we design that tissue material a In of Axoguard features gel on healing gliding The the form the year. our remodeled adds minimizing material. long-term clearance attachment. gel the builds enhances is nerve in received protective an and Axoguard process, announce hyaluronate-alginate short-term new tissue of layer ECM to based new, HA+ this aids soft base in upon a layer. success and happy features. XXX(k) protector April new We’re Protector This existing proprietary
such address In and addition improves portfolio and protection major believe characteristics critical. the challenging nerve trauma Axoguard We to these mobility to Axoguard this to where of surgeon revisions optimized benefits, handling applications is as to this protection the nerve access addition our based were cubital near joints HA+ tunnel feedback configuration nerve on category. nerve
for separation see strengthen nerve Additionally, forward surgeon we protection. of need this Avive interest nerve and solution market innovation the to in you important continue product protection to on Membrane. We a position this the phase We're strong nerve to this This and protection we'll coming by will the that expect our application previously critical updating replacement and in look during temporary further was healing developing resorbable opportunity injuries. provides addressed that non-transected for Tissue address Soft currently – a new quarter. tissue that
BLA we XXXX. by Graft. in Coming our included the track BLA to the will expected on with This plans our for APC will that new we're in and be also transition submit and Nerve the which production on to Avance support facility, new for happy schedule, Ohio summer. to our to facility This to end it I'm our sales state-of-the-art proceeding this is growth expect of facility the Dayton, report Avance, meet submission capacity of provide
a Nerve XX receiving importantly, Avance BLA based of in designated a in Graft product to product, XXXX. biosimilars. to data of potential believe complete reference product. as with anticipate we would that, XXX-biological XXX exclusivity turn regulatory Following we A from approval the which will approval provide And Avance would be the regard transition years
with nerve healthcare of continue repair build for particularly direct-to-patient initiatives, providers pain market to applications. awareness and We through our and breast
engage to nerve pain educating repair benefits designed our at about procedures. and websites. websites are and resensation patients the initiatives patients to them are of marketing Our awareness direct raising These aimed potential and rethink
chronic resources for In undergoing neuropathic and in skilled addition, surgeons for are available patient advanced suffering particularly techniques, individuals pain. these and locating mastectomy reconstruction, for those from
repair remain for Our surgeon programs and generate to AxoGen community. top continue the on education interest priority in surgical a nerve
goal hands-on encompass education presentations of learning surgical wide our including educational and XX% of At we practices surpassed of this at conferences training year's of Our the trainings, hand at fellows. end microsurgery aimed a residents. of class best and QX, least initiatives events, range
remain body XXX of peer of quality nerve the evidence. trauma, the – utility in our end updates Moving across total We clinical developing on and to our of evidence reviewed performance At safety, solutions. demonstrate to extremity, a growing repair to devoted pain. clinical reached of and the publications clinical OMF we've quarter, breast,
high priority. providing quality remains alternative to on focus allograft Our peripheral top of the repair benefits nerve over a data technique support
recently in discussed our from quarter, been the meta-analysis has customers. study we've a published comparative generating previous interest significant As effectiveness
sensory and harvesting to that short recovery with efficacy this and without allograft the nerve To rates analyzed for summarize, XX comparable types compared and peer millimeters nerve. well-documented had gap authors Conduits. in up between reviewed studies and autograft associated both to morbidities The the long autograft XX found meaningful Allograft, Autograft and both motor paper
Additionally, additional the Medicare and paper and XXXX. included autograft facility quarter, second found from the payer retrospective procedure were publication autograft that nerve reviewed to both costs operative over inpatient were see in procedure the XXXX study the database settings. of repairs part costs comparable peer study of between and and X,XXX and premier comprehensive the compared we outpatient This allograft early an In all repairs. for comparing allograft costs delighted both
costs that there conclusions the autograft comparing significant were were or and when repair either they findings in of with no in where consistent the difference author's setting. procedure inpatient The outpatient meta-analysis noted allograft the
inpatient hospitals, that OR allograft repairs and out significantly Additionally, shorter resource settings. in authors the constrained and both for for concluded was importantly time
to we Turning the million. revenue now start plan. release, $XXX forward year reiterated to year guidance range look the of continuing outlook. today's execute pleased full $XXX XXXX to million with of the and to our press our We're In our on with in
to to gross XXXX. will new the expect return with and by that will fourth of margin approximately quarter margins the expect continue gross processing transition be the XX% reduced facility to We company's
financial Now turn Pete of for to call a review highlights. over the Pete?
